Share chart Eloxx Pharmaceuticals, Inc.
Extended chart
Simple chart
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., биофармацевтическая компания клинической стадии, занимается разработкой модуляции рибосом для лечения редких и ультраредких преждевременных заболеваний стоп-кодонов. Его ведущим кандидатом в исследуемый лекарственный продукт является ELX-02, который находится на стадии 2 клинических испытаний для лечения пациентов с муковисцидозом и нефропатическим цистинозом с диагностированными нонсенс-мутациями. more detailsMain settings
| IPO date | 2018-01-19 |
|---|---|
| ISIN | US29014R1032 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | link |
| Change price per day: | 0% (0.0001) |
|---|---|
| Change price per week: | 0% (0.0001) |
| Change price per month: | 0% (0.0001) |
| Change price per 3 month: | -99.99% (0.7501) |
| Change price per half year: | 0% (0.0001) |
| Change price per year: | -99.99% (0.8264) |
| Change price per 3 year: | -99.97% (0.3265) |
| Change price per 5 year: | -100% (2.78) |
| Change price per year to date: | 0% (0.0001) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 0 | 0 |
| P/BV | -0.4146 | 0 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -109 | 0 |
| ROE, % | -616.05 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.3895 | 10 |
| Debt/Ratio | 0.6351 | 9 |
| Debt/Equity | -2.97 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | -62.5 | 0 |
| Yield Ebitda, % | -43.6 | 0 |
| Yield EPS, % | -70.64 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Armistice Capital, LLC | 275 000 | 8.75 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 54 075 | 1.72 |
| Menora Mivtachim Holdings Ltd. | 52 355 | 1.67 |
| American Financial Group Inc. | 37 000 | 1.18 |
| Altshuler Shaham Ltd | 25 123 | 0.8 |
| Vanguard Group Inc | 20 786 | 0.66 |
| Geode Capital Management, LLC | 19 588 | 0.62 |
| Clal Insurance Enterprises Holdings Ltd | 13 526 | 0.43 |
| Atom Investors LP | 10 638 | 0.34 |
| Blackrock Inc. | 8 870 | 0.28 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Sumit Aggarwal M.B.A. | President, CEO & Director | 839.67k | 1973 (52 years) |
| Ms. Barbara Ryan | Investor Relations Officer | N/A | |
| Dr. Ali Hariri M.D. | Chief Medical Officer | N/A | |
| Mr. Daniel E. Geffken M.B.A. | Interim CFO, Principal Financial Officer & Principal Accounting Officer | 63.96k | 1957 (68 years) |
About company
Address: United States, Watertown. MA, 480 Arsenal Way - Open in google maps, Open in yandex maps
Website: https://www.eloxxpharma.com
Website: https://www.eloxxpharma.com
